FENC vs. TECX, CGEM, AUTL, CRGX, HUMA, OPT, MGTX, PROK, TRML, and AURA
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Tectonic Therapeutic (TECX), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), CARGO Therapeutics (CRGX), Humacyte (HUMA), Opthea (OPT), MeiraGTx (MGTX), ProKidney (PROK), Tourmaline Bio (TRML), and Aura Biosciences (AURA). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals vs.
Tectonic Therapeutic (NASDAQ:TECX) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.
Fennec Pharmaceuticals received 193 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 66.45% of users gave Fennec Pharmaceuticals an outperform vote.
Tectonic Therapeutic currently has a consensus target price of $72.25, indicating a potential upside of 54.58%. Fennec Pharmaceuticals has a consensus target price of $13.67, indicating a potential upside of 119.37%. Given Fennec Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Fennec Pharmaceuticals is more favorable than Tectonic Therapeutic.
Tectonic Therapeutic has higher earnings, but lower revenue than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.
Tectonic Therapeutic has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.
In the previous week, Tectonic Therapeutic had 3 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 4 mentions for Tectonic Therapeutic and 1 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 0.94 beat Tectonic Therapeutic's score of 0.58 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.
Tectonic Therapeutic has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Tectonic Therapeutic's return on equity of -35.53% beat Fennec Pharmaceuticals' return on equity.
62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 11.0% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Tectonic Therapeutic and Fennec Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:FENC) was last updated on 1/25/2025 by MarketBeat.com Staff
